24/7 Market News Snapshot 22 October, 2024 – ZyVersa Therapeutics, Inc. Common Stock (NASDAQ:ZVSA)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:ZVSA) are discussed in this article.
ZyVersa Therapeutics, Inc. (ZVSA) has captured market attention with a notable pre-market surge, trading at $2.869, reflecting a remarkable increase of 24.74% from the prior close of $2.300. The trading volume of 1.31 million shares indicates strong investor interest and optimism surrounding the biotech firm, which is recognized for its pioneering therapeutic approaches. This bullish activity aligns with the company’s ongoing advancements in addressing obesity-related health issues, particularly those linked to neuroinflammation and neurodegenerative diseases.

Recent research published in Aging Cell has drawn attention to the relationship between obesity-induced inflammation and its detrimental effects on brain health, specifically in the context of Alzheimer’s and Parkinson’s diseases. The study demonstrates that chronic obesity escalates neuroinflammation, highlighting the urgent need for effective therapeutic solutions. In response, ZyVersa has positioned its lead invention, the Inflammasome ASC Inhibitor, IC 100, as a promising candidate to target and reduce the neuroinflammatory processes associated with these conditions.

Stephen C. Glover, Co-founder, Chairman, CEO, and President of ZyVersa, emphasized the innovative potential of IC 100, particularly its ability to affect critical organs impacted by obesity, including the brain. The recent in vitro data, supported by funding from the Michael J. Fox Foundation, has bolstered the product’s prospects in mitigating neuroinflammation indicative of Parkinson’s disease.

The researchers conducted studies utilizing a diet-induced obesity mouse model, which revealed concerning trends such as significant weight gain and pronounced systemic inflammation affecting vital brain regions. The insights gleaned from this research underscore the importance of addressing obesity to prevent compounded health challenges. Continuing its commitment to tackling significant unmet medical needs, ZyVersa is poised to initiate further investigations into the efficacy of IC 100 in Parkinson’s disease models, setting the stage for impactful therapeutic advancements.

Related news for (ZVSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.